Skip to main content

From neuroimmunology to Alzheimer’s disease and dementia testing, neurological testing can help provide answers

Behind every sample is a life—a life filled with questions. We help provide answers with our broad menu of over 400 neurology tests, including a full portfolio for Alzheimer’s disease and dementia testing, as well as expansive testing for complex  neuroimmunological diseases and other neurological conditions.

Insights to help improve outcomes

The complexity of the neurological system and the absence of a specific clinical presentation make it difficult to know where to look first. In most cases, early detection and prompt therapy can improve patient outcomes.1 We offer a comprehensive neurological testing portfolio, including blood and CSF testing methods, so you can provide the answers and care your patients deserve.


QUEST AD-Detect™ Amyloid Beta 42/40 Ratio

Assessing risk for Alzheimer’s disease, the most common form of dementia 


Alzheimer’s disease affects over 6M people in the US2 and may contribute to up to 70% of cases of dementia.3 Quest offers a simple blood-based, easily accessible risk assessment options that can directly impact your care pathway.

Quest Ad Detect

Your source for autoimmune neurology testing

Neuroimmunological diseases are complex. Testing for them shouldn’t be. Quest Advanced® Neurology has expanded offerings for several autoimmune neurological disorders and makes testing more accessible and actionable.


Broad neuroimmunology menu

Expansive test menu includes over 40 antibodies


Our neuroimmunology portfolio includes testing for myasthenia gravis, paraneoplastic syndromes, autoimmune encephalitis, neuromyelitis optica, peripheral neuropathy, and multiple sclerosis. Our expansive test menu includes over 40 antibodies and utilizes gold-standard methodologies, such as CBA, RIA, and line blot.4

Image showing doctor talking with a patient

We help eliminate the unknowns

No matter where each patient is on the diagnostic journey, our complete portfolio of molecular, biochemical, neuroimmunological, cytogenetic, and pharmacogenomic testing can help you and your patient move forward with clarity and confidence.

Watch Video

A comprehensive range of neurology testing, powered by 15 distinct methodologies

In the US, 1 in 9 people over 65 has Alzheimer’s disease,2 but there is evidence that early detection and emerging treatments can lessen its impact. 

Quest Advanced® Neurology offers a full portfolio of industry-leading diagnostics to assess the risk of Alzheimer’s disease and dementia, whether your patient has a family history or not.

Our neuroimmunology portfolio includes testing for myasthenia gravis, paraneoplastic syndromes, autoimmune encephalitis, neuromyelitis optica, peripheral neuropathy, and multiple sclerosis. Our expansive test menu includes over 40 antibodies and utilizes gold-standard methodologies, such as CBA, RIA, and line blot.4

Research shows that early interventions for ASD and developmental delay can greatly improve a child’s development. We offer AAP guideline-based chromosomal microarray analysis (CMA),5 which has the highest diagnostic yield of any single test for children that is currently available to clinicians.

IEM happen when a genetic defect disrupts the body’s metabolic pathway—causing conditions such as vitamin deficiencies, organic acidemia, and peroxisomal disorders. Because the balance between undertreatment and overtreatment can be precarious, ongoing monitoring is essential. Get the  insights you need to manage IEM-derived challenges with our comprehensive genetic test menu and on-demand expertise from genetic counselors.

Identify a patient’s unique stroke risk and take action by assessing their metabolic and cardiovascular risk profile. Quest offers a full range of stroke testing that can help inform care plans and treatment monitoring. 


The power of Quest


  1. Vincent A, Bien CG, Irani SR, et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011;10(8):759-772. doi:10.1016/S1474-4422(11)70096-5
  2. Alzheimer’s Association. 2023 Alzheimer’s Disease Facts and Figures. 2023.
  3. WHO. Dementia. March 15, 2023. Accessed July 5, 2023.
  4. Stocker W, Probst C, Teegen B, et al. Multiparameter autoantibody screening in the diagnosis of neurological autoimmune diseases. Paper presented at: 1st Congress of the European Academy of Neurology (EAN); June 2015; Berlin, Germany.
  5. Sathirapongsasuti JF, Lee H, Horst BA, et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics. 2011;27(19):2648-2654. doi:10.1093/bioinformatics/btr462
  6. CDC. Accelerating risk reduction and promoting brain health. Updated July 29, 2019. Accessed May 18, 2023.